Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,006 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophagus Neoplasm Clear all
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 23, 2026, 2:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

NCT07405151
View directory record Official record
Conditions
Oesophageal Squamous Cell Carcinoma
Interventions
I-DXd, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 2:29 AM EDT
Recruiting No phase listed Observational

A Multicenter Cancer Biospecimen Collection Study

NCT04510129
View directory record Official record
Conditions
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Interventions
OncoPrism™ assay
Diagnostic Test
Lead sponsor
Cofactor Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

NCT00590031
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Cisplatin, Irinotecan, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 23, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

NCT07070466
View directory record Official record
Conditions
Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
Interventions
Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Santa Monica, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586
View directory record Official record
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 23, 2026, 2:29 AM EDT
Recruiting Phase 4 Interventional

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

NCT07124351
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastric Cancer, Esophageal Cancer, Appendiceal Cancer
Interventions
CYTALUX™ (pafolacianine)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 23, 2026, 2:29 AM EDT
Completed No phase listed Observational

Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer

NCT02372929
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Endoscopic Ultrasound
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 23, 2026, 2:29 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

NCT00431756
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Neoplasm, Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Withdrawn Not applicable Interventional

Monopolar and Bipolar in Esophageal ESD

NCT05736705
View directory record Official record
Conditions
Esophageal Neoplasm, Esophageal Polyp, Endoscopic Submucosal Dissection, Bipolar Electocautery
Interventions
Endoscopic Submucosal Dissection, Bipolar electrocautery knife
Procedure · Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 23, 2026, 2:29 AM EDT
Completed No phase listed Observational

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

NCT01393483
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma
Interventions
serum and tissue mesothelin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 23, 2026, 2:29 AM EDT
Not listed No phase listed Observational

TRIAD Burden of Illness Mucositis Study

NCT00336609
View directory record Official record
Conditions
Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine)
Interventions
Not listed
Lead sponsor
TRIAD Burden of Illness
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2007 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery

NCT00505024
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer
Interventions
Interactive Voice Response System, Symptoms Report
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 23, 2026, 2:29 AM EDT
Completed No phase listed Observational

Gravity Assisted Technique for Esophageal Endoscopic Submucosal Dissection (ESD)

NCT04547881
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

NCT00130689
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Neoplasm Metastasis
Interventions
Cetuximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 23, 2026, 2:29 AM EDT
Completed No phase listed Observational

Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus

NCT01281618
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
24 hour pH study and upper endoscopy (EGD)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 23, 2026, 2:29 AM EDT
Completed No phase listed Observational

Racial Disparity in Barrett's Esophagus

NCT01374074
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Intestinal Metaplasia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 23, 2026, 2:29 AM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766
View directory record Official record
Conditions
Gastrointestinal Tract Malignancies
Interventions
Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Active, not recruiting Early Phase 1 Interventional

Itraconazole to Prevent Recurrent Barrett's Esophagus

NCT05609253
View directory record Official record
Conditions
Barrett Oesophagitis With Dysplasia
Interventions
Itraconazole in capsule form, Itraconazole in solution form
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

NCT03042611
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma
Interventions
Rivoceranib, Placebo
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

NCT00176800
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Tetrathiomolybdate (TM), Radiation, Surgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2Phase 3 Interventional

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

NCT00002930
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer
Interventions
positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 23, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 2:29 AM EDT